L

LivaNova PLC (LIVN)

NMS – Real vaqt narxi. Valyuta: USD

71.75

+1.66 (2.37%)

Yopilishda: May 12, 2026, 4:00 PM EDT

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Barcha huquqlar himoyalangan.

Foydalanish shartlari

L

LivaNova PLC (LIVN)

NMS – Real vaqt narxi. Valyuta: USD

71.75

+1.66 (2.37%)

Yopilishda: May 12, 2026, 4:00 PM EDT

11.05.2026

LivaNova (LIVN) Upgraded to Buy: Here's What You Should Know

LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

06.05.2026

LivaNova PLC (LIVN) Q1 2026 Earnings Call Transcript

06.05.2026

LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates

LivaNova (LIVN) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.88 per share a year ago.

06.05.2026

LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) First-quarter revenue of $362.3 million increased 14.3% on a reported basis and 11.1% on a constant-currency basis as compared to the prior-year period First-quarter U.S. GAAP diluted earnings per share of $0.40 and adjusted diluted earnings per share of $0.98 F.

20.04.2026

Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea

LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal Medicine has published an article chronicling the full 12-month data set for the Company's OSPREY randomized controlled trial (RCT). The researchers evaluated the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality, when delivered by LivaNova's aura6000™ System for the treatment of mod.

25.03.2026

LivaNova Expands OSA Care With FDA-Approved aura6000 System

LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.

25.03.2026

LivaNova to Announce First-Quarter 2026 Results

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its first-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen.

Videolar

No Data

There is no data to display

Press-relizlar

06.05.2026

LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) First-quarter revenue of $362.3 million increased 14.3% on a reported basis and 11.1% on a constant-currency basis as compared to the prior-year period First-quarter U.S. GAAP diluted earnings per share of $0.40 and adjusted diluted earnings per share of $0.98 F.

20.04.2026

Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea

LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal Medicine has published an article chronicling the full 12-month data set for the Company's OSPREY randomized controlled trial (RCT). The researchers evaluated the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality, when delivered by LivaNova's aura6000™ System for the treatment of mod.

19.03.2026

LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000™ System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea (OSA). The System utilizes proximal hypoglossal nerve stimulation (p-HGNS), a differentiated neurostimulation modality, to treat OSA in patients with an apnea-hypopnea index (AHI) between 15 and 65.

25.02.2026

LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance

LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2025 results and issued full-year 2026 guidance. Financial Summary and Highlights(1) Fourth-quarter revenue of $360.9 million increased 12.1% on a reported basis and 9.5% on both a constant-currency and organic basis as compared to the prior-year period Fourth-quarter U.S. GAAP diluted earnings per share of $0.56 and adjusted diluted earnings per share o.

Search stocks

LivaNova PLC (LIVN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

LivaNova PLC (LIVN)

LivaNova (LIVN) Upgraded to Buy: Here's What You Should Know

LivaNova PLC (LIVN) Q1 2026 Earnings Call Transcript

LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates

LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea

LivaNova Expands OSA Care With FDA-Approved aura6000 System

LivaNova to Announce First-Quarter 2026 Results

Videolar

No Data

Press-relizlar

LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea

LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance